Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curaleish Lotion and Cream for Cutaneous Leishmaniasis
NCT04072874Phase 2
Key facts
- Status
- Withdrawn
- Start
- Jan 2021
- Primary completion
- Feb 2021
- Countries
- 1
- Sponsor
- Universidad de Antioquia
- Modality
- Hydrogel Systems, Transdermal Patches
- Drugs
- curaleish
- Conditions
- cutaneous leishmaniasis (CL)
01
Overview
Phase 2, randomised, open-label trial of curaleish in cutaneous leishmaniasis (CL) (2 arms), sponsored by Universidad de Antioquia. Primary endpoint: Post treatment healing at Day 180. Planned start Jan 2021; status: withdrawn.
02
Design
2 arms- Study design
- RandomizedOpen-label
Regimen 1 (4 weeks)
Curaleish lotion and cream for 4 weeks
Regimen 2 (6 weeks)
Curaleish lotion and cream for 6 weeks
03
Endpoints
Primary
Post treatment healing
Secondary
Adverse events
Re-epithelialization of lesions
Beyond the preview
Go deeper on NCT04072874.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072874.